Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
318 results
- (DECIDE)Complete statistical analysis of the phase 3 DECIDE trial comparing BIIB019 (daclizumab high yield process) with interferon beta-1a in participants with relapsing-remitting multiple sclerosis, including trial design, registered endpoints, regression methods, efficacy…
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- 65plusIndependent statistical analysis of Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features: Complete Statistical AnalysisIndependent statistical analysis of A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features: primary endpoint results,…
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056): Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056): primary endpoint results, effect estimate…
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy: Complete Statistical AnalysisIndependent statistical analysis of A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): primary endpoint results, effect…
- A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor: Complete Statistical AnalysisIndependent statistical analysis of A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor: primary endpoint results,…
- A Phase III Trial For Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Phase III Trial For Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00191152).
- A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans: Complete Statistical AnalysisIndependent statistical analysis of A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01514760).
- A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark: Complete Statistical AnalysisIndependent statistical analysis of A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark: primary endpoint results, effect estimate with…
- A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP): Complete Statistical AnalysisIndependent statistical analysis of A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Safety and Efficacy Study of Tralokinumab in Adults With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Efficacy Study of Tralokinumab in Adults With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen: Complete Statistical AnalysisIndependent statistical analysis of A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen: primary endpoint results, effect…
- A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma: Complete Statistical AnalysisIndependent statistical analysis of A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010): Complete Statistical AnalysisIndependent statistical analysis of A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010): primary endpoint results, effect estimate with confidence interval,…
- A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission:…
- A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation: Complete Statistical AnalysisIndependent statistical analysis of A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation: primary endpoint results, effect estimate…
- A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132): Complete Statistical AnalysisIndependent statistical analysis of A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV…
- A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007): Complete Statistical AnalysisIndependent statistical analysis of A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007): primary endpoint results, effect estimate with confidence…
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST): Complete Statistical AnalysisIndependent statistical analysis of A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of E7820 in People With Bone Marrow (Myeloid) Cancers: Complete Statistical AnalysisIndependent statistical analysis of A Study of E7820 in People With Bone Marrow (Myeloid) Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations: Complete Statistical AnalysisIndependent statistical analysis of A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations: primary endpoint results, effect estimate with confidence interval,…
- A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM): Complete Statistical AnalysisIndependent statistical analysis of A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01280552).
- A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00862784).
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy: primary endpoint results, effect estimate with confidence…
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus: Complete Statistical AnalysisIndependent statistical analysis of A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus: primary endpoint results, effect estimate…
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Paliperidone Palmitate 6-Month Formulation: Complete Statistical AnalysisIndependent statistical analysis of A Study of Paliperidone Palmitate 6-Month Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03345342).
- A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06): primary endpoint results, effect estimate…
- A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): primary…
- A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN): Complete Statistical AnalysisIndependent statistical analysis of A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN): primary endpoint results, effect estimate with confidence…
- A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery: Complete Statistical AnalysisIndependent statistical analysis of A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer: primary endpoint…
- A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary…
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer: primary endpoint results, effect estimate with confidence interval,…
- A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission: primary endpoint results, effect estimate…
- A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval,…